Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16201 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Paul Healy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Therapeutics Group, University College London, London, UK. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Tramadol, Analgesics, Opioid, Octamer Transcription Factor-1. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Seventh Framework Programme.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Aims
Our investigation aimed to assess the dose rationale of tramadol in paediatric patients considering the effect of CYP2D6/OCT1 polymorphisms on systemic exposure. Recommendations were made for the oral dose of tramadol to be used in a prospective study in children (3 months to < 18 years old) with chronic pain.
Methods
Intravenous pharmacokinetic and genotype data from neonatal patients ( n = 46) were available for this analysis. The time course of tramadol and O‐desmethyltramadol (M1) concentrations was characterized using a nonlinear mixed effects approach in conjunction with extrapolation principles. Clinical trial simulations were then implemented to explore the effects of polymorphism, maturation and developmental growth on the disposition of tramadol and M1. Reported efficacious exposure range in adult subjects were used as reference.
Results
The pharmacokinetics of tramadol and M1 was characterized by a two‐compartment model. The total clearance of tramadol (CLPP) comprised CYP2D6‐mediated metabolism (CLPM) and other pathways (CLPO). Age‐related changes in CLPM, CLPO and M1 clearance (CLMO) were described by a sigmoid function, with CYP2D6 as a covariate on CLPP and CLPM, and OCT1 on CLMO. Simulation scenarios including different CYP2D6/OCT1 combinations revealed that steady‐state concentrations are above the putative ranges for analgesia in >15% and >70% of subjects after doses of 3 and 8 mg/kg, respectively.
Conclusions
In the absence of genotyping, reference exposure ranges can be used to define the dose rationale for tramadol in paediatric chronic pain. However, a starting dose of 0.5 mg/kg/day should be considered, followed by stepwise titration to the desired analgesic response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Therapeutics Group, University College London, London, UK.
- Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands.
- Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, London, UK.
ORCID-Profile: Oscar Della Pasqua
Förderung
- European Union's Seventh Framework Programme
Zitieren
APA
Healy, P., Allegaert, K., & Della Pasqua, O. (2025). Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16201
Vancouver
Healy P, Allegaert K, Della Pasqua O. Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16201
BibTeX
@article{Healy2025,
author = {Healy, Paul and Allegaert, Karel and Della Pasqua, Oscar},
title = {Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16201}
}
EUVIMED